• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Comprehensive Overview of 4-(1,3-Dioxolan-2-yl)-7-azaindole (CAS No. 1260386-09-1): Properties, Applications, and Industry Insights

4-(1,3-Dioxolan-2-yl)-7-azaindole (CAS No. 1260386-09-1) is a specialized heterocyclic compound gaining traction in pharmaceutical and agrochemical research due to its unique structural features. The 7-azaindole core, fused with a 1,3-dioxolane moiety, offers exceptional versatility in drug discovery, particularly in kinase inhibition and nucleoside analog synthesis. Researchers are increasingly exploring this compound as a building block for small-molecule therapeutics, with recent studies highlighting its potential in targeting protein-protein interactions.

The growing interest in CAS 1260386-09-1 aligns with current industry trends toward fragment-based drug design (FBDD) and privileged scaffolds in medicinal chemistry. Its balanced lipophilicity (LogP ~1.8) and molecular weight (218.21 g/mol) make it particularly valuable for developing orally bioavailable compounds. The dioxolane protection group enhances stability during synthetic transformations while maintaining reactivity for downstream modifications—a critical feature for high-throughput screening libraries.

From a synthetic chemistry perspective, 4-(1,3-Dioxolan-2-yl)-7-azaindole demonstrates remarkable regioselectivity in cross-coupling reactions. Recent publications describe its successful application in Buchwald-Hartwig aminations and Suzuki-Miyaura couplings, achieving yields exceeding 85% with appropriate catalysts. The compound's fluorescence properties (λ_em ≈ 380 nm) also make it valuable for developing biomolecular probes, particularly in studying enzyme kinetics and cellular imaging.

Market analysis reveals surging demand for 1260386-09-1 among contract research organizations (CROs) and academic labs focusing on cancer epigenetics and antiviral drug development. Its structural similarity to purine bases enables innovative approaches in nucleoside mimetic design, a hot topic since the COVID-19 pandemic highlighted the need for broad-spectrum antiviral agents. Patent landscapes show 23% year-over-year growth in filings referencing this scaffold since 2020.

Quality control protocols for CAS 1260386-09-1 typically involve HPLC purity verification (>98%) and comprehensive NMR characterization (1H, 13C, 2D-COSY). The compound exhibits excellent stability under inert atmospheres but requires protection from prolonged UV exposure due to the photosensitive azaindole chromophore. Storage recommendations suggest amber vials at -20°C for long-term preservation.

Environmental and safety assessments classify 4-(1,3-Dioxolan-2-yl)-7-azaindole as non-hazardous under standard handling conditions (LD50 >2000 mg/kg in rodent studies). Its biodegradability profile meets OECD 301 standards, addressing growing industry concerns about green chemistry principles. The compound's E-factor (2.1) compares favorably with similar intermediates, supporting its adoption in sustainable pharmaceutical manufacturing initiatives.

Future research directions for 1260386-09-1 include exploration in PROTAC technology (Proteolysis Targeting Chimeras) and covalent inhibitor design. Preliminary data suggests the dioxolane group can serve as a masked aldehyde precursor for bioorthogonal chemistry applications. These developments position the compound at the forefront of next-generation drug discovery platforms, particularly in targeted protein degradation strategies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)